Is GILD a good stock to buy? We came across a bullish thesis on Gilead Sciences, Inc. on Trevor Young’s Substack. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $135.87 as of April 20th. GILD’s trailing and forward P/E were 20.04 and 15.50 respectively according to Yahoo Finance.
Copyright: dolgachov / 123RF Stock Photo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. GILD exemplifies a “Safe Atom” in the Barbell Strategy, providing stability, predictable cash flow, and disciplined capital allocation amid a volatile biotech landscape. While often criticized for slower top-line growth relative to AI-driven drug discovery startups, Gilead’s entrenched leadership in the HIV market acts as a utility-like engine, generating reliable revenue and underpinning a strong dividend track record.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
As of March 2026, Gilead’s quarterly dividend of $0.82 per share yields approximately 2.4%, supported by a payout ratio under 50%, allowing the company to fund its R&D pipeline while maintaining significant financial flexibility. With a beta well below the S&P 500, GILD offers low-volatility ballast for investors, providing steady returns even when high-risk growth bets experience turbulence.
The investment thesis centers on “paid patience,” waiting for two key catalysts to unlock additional upside. First, the rollout of Lenacapavir, a twice-yearly long-acting HIV therapy, positions Gilead to defend and extend its market leadership against competitors like ViiV, potentially creating durable growth for the next decade. Second, the maturation of the oncology segment through the Kite Pharma acquisition is delivering steady, high-margin expansion, diversifying revenue beyond a single therapeutic area without relying on speculative breakthroughs.
Gilead’s fundamentals remain robust, with HIV market share consistently above 70%, a stable debt-to-equity profile, and strong returns on equity around 42%. While GILD is not a “moonshot” stock, it delivers essential cash flow, low volatility, and disciplined capital deployment, making it a cornerstone for conservative portfolios. Its combination of steady dividends, high-margin core businesses, and strategic growth catalysts offers a compelling opportunity for investors to earn while waiting for longer-term expansion in both HIV and oncology segments.
Previously, we covered a bullish thesis on Gilead Sciences, Inc. (GILD) by Disruptive Analytics in February 2025, which highlighted revenue headwinds from the Inflation Reduction Act, a strong dollar, and lower COVID-related hospitalizations, while noting solid cost discipline and a fair value estimate of $115. GILD’s stock price has appreciated by approximately 30.54% since our coverage. Trevor Young shares a similar view but emphasizes Gilead’s “Safe Atom” status, focusing on stable cash flow, disciplined dividends, and long-acting HIV therapy as key catalysts for patient investors.
Gilead Sciences, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 71 hedge fund portfolios held GILD at the end of the fourth quarter which was 61 in the previous quarter. While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
